Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2500 participants
OBSERVATIONAL
2020-03-24
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Classification of COVID-19 Infection in Posteroanterior Chest X-rays
NCT04358536
Computed Tomography for COVID-19 Diagnosis
NCT04355507
Multicenter Validation Study of an Artificial Intelligence Tool for Automatic Classification of Chest X-rays
NCT04991987
Application of Mobile DR in the Diagnosis of Bone Trauma in High Cold Environment
NCT05440435
Risk Factors and Computed Tomography Findings in COVID-19.
NCT04577105
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, it has been widely demonstrated that, even at early stages of the disease, chest x-rays (CXR) and computed tomography (CT) scans can show pathological findings. It should be noted that they are actually non specific, and overlap with other viral infections (such as influenza, H1N1, SARS and MERS): most authors report peripheral bilateral ill-defined and ground-glass opacities, mainly involving the lower lobes, progressively increasing in extension as disease becomes more severe and leading to diffuse parenchymal consolidation, CT is a sensitive tool for early detection of peripheral ground glass opacities; however routine role of CT imaging in these Patients is logistically challenging in terms of safety for health professionals and other patients, and can overwhelm available resources. Chest X-ray can be a useful tool, especially in emergency settings: it can help exclude other possible lung "noxa", allow a first rough valuation of the extent of lung involvement and most importantly can be obtained at patients bed using portable devices, limiting possible exposure in health care workers and other patients. Furthermore, CXR can be repeated over time to monitor the evolution of lung disease.
Methodology:
we describe the deeplearning approach based on quite standard pipeline, namely chest image pre-processing and lung segmentation followed by classification model obtained with transfer learning. As we will see in this section, data pre-processing is fundamental to remove any bias present in the data. In particular, we will show that it is easy for a deep model to recognize these biases which drive the learning process. Given the small size of COVID datasets, a key role is played by the larger datasets used for pre-training. Therefore, we first discuss which datasets can be used for our goals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
interstitial pneumonia cases
Chest x-ray diagnosis
Neural network diagnosis algorithm
we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
Negative controls
Chest x-ray Negative for pneumonia
Neural network diagnosis algorithm
we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neural network diagnosis algorithm
we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Turin, Italy
OTHER
Azienda Ospedaliera Ordine Mauriziano di Torino
OTHER
A.O.U. Città della Salute e della Scienza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giorgio Limerutti
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giorgio Limerutti, M.D.
Role: PRINCIPAL_INVESTIGATOR
Radiology Unit A.O.U. Città della Salute e della Scienza
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliero Universitaria Città della Salute e della Scienza
Torino, Turin, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CORDA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.